Literature DB >> 15869050

Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I.

Athanassios Manginas1, Evgenia Bei, Antigoni Chaidaroglou, Dimtrios Degiannis, Katerina Koniavitou, Vassilis Voudris, Gregory Pavlides, Demosthenis Panagiotakos, Dennis V Cokkinos.   

Abstract

BACKGROUND: Acute coronary syndromes (ACS) are characterized by activation of systemic and local inflammatory mediators. The interrelation between these soluble inflammatory markers and their association with markers of myocardial necrosis have not been extensively studied. HYPOTHESIS: The study was undertaken to evaluate the association of the systemic levels of matrix metalloproteinase-9 (MMP-9) and the tissue inhibitor of metalloproteinase-1 (TIMP-1), with C-reactive protein (CRP), interleukin-6 (IL-6), and serum troponin-I in patients admitted with ACS.
METHODS: Analysis of serum concentrations of the above inflammatory markers was performed in 53 patients with unstable angina (UA) and in 15 with non-ST-segment elevation myocardial infarction (NSTEMI) within 48 h of admission, and 34 patients with stable coronary artery disease.
RESULTS: Compared with patients with stable angina, those with ACS had elevated admission levels of MMP-9 (p = 0.04), CRP (p < 0.001), and IL-6 (p = 0.001), but not TIMP-1 (p = 0.55). Compared with patients with UA, those with NSTEMI also had higher levels of IL-6 (p < 0.001), CRP (p = 0.002), and MMP-9 (p = 0.05).
CONCLUSIONS: In patients with ACS, the admission levels of inflammatory mediators, including MMP-9, CRP, and IL-6 are significantly elevated, specifically in association with serum troponin I. Systemic and local markers of inflammatory activity may be directly associated with myocardial injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869050      PMCID: PMC6654195          DOI: 10.1002/clc.4960280405

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  9 in total

1.  Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens.

Authors:  Kathryn Thrailkill; Gael Cockrell; Pippa Simpson; Cynthia Moreau; John Fowlkes; R Clay Bunn
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

2.  Matrix metalloproteinase therapy in heart failure.

Authors:  Francis G Spinale; Nikole M Wilbur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

3.  Interleukin-6 and Hospital Length of Stay after Open-heart Surgery.

Authors:  Amy L Ai; Daniel Hall; Steven F Bolling
Journal:  Biol Psichiatr Psichofarmakol       Date:  2012-12

4.  Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome.

Authors:  Min Cheng; Satwat Hashmi; Xiaobo Mao; Qiu Tang Zeng
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

5.  Concentration kinetics of serum MMP-9 and TIMP-1 after blunt multiple injuries in the early posttraumatic period.

Authors:  M Brumann; T Kusmenkov; L Ney; K-G Kanz; B A Leidel; P Biberthaler; W Mutschler; V Bogner
Journal:  Mediators Inflamm       Date:  2012-03-27       Impact factor: 4.711

6.  Circulating Porphyromonas gingivalis lipopolysaccharide resets cardiac homeostasis in mice through a matrix metalloproteinase-9-dependent mechanism.

Authors:  Kristine Y Deleon-Pennell; Lisandra E de Castro Brás; Merry L Lindsey
Journal:  Physiol Rep       Date:  2013-10-02

7.  Silencing RNA for MMPs May Be Utilized for Cardioprotection.

Authors:  Marta Banaszkiewicz; Anna Krzywonos-Zawadzka; Agnieszka Olejnik; Agnieszka Noszczyk-Nowak; Iwona Bil-Lula
Journal:  Cardiovasc Ther       Date:  2022-08-24       Impact factor: 3.368

Review 8.  The inflammatory response to miniaturised extracorporeal circulation: a review of the literature.

Authors:  Hunaid A Vohra; Robert Whistance; Amit Modi; Sunil K Ohri
Journal:  Mediators Inflamm       Date:  2010-01-13       Impact factor: 4.711

9.  Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway.

Authors:  Nouf M Al-Rasheed; Maha M Al-Oteibi; Reem Z Al-Manee; Sarah A Al-Shareef; Nawal M Al-Rasheed; Iman H Hasan; Raeesa A Mohamad; Ayman M Mahmoud
Journal:  Drug Des Devel Ther       Date:  2015-06-23       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.